Q-omics provides the consensus-scored KRTAP22-2 profile across patient tissues and cancer cell-line models. KRTAP22-2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KRTAP22-2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, KRTAP22-2 RNA expression shows 8,564 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, PRAD, and TGCT as cancer lineages where KRTAP22-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP22-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP22-2 survival associations across molecular data types. KRTAP22-2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP22-2 RNA expression–survival associations across cancer types. High KRTAP22-2 expression shows unfavorable associations in LIHC, UCEC, KIRP, UCS, THCA and STAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KRTAP22-2 RNA expression.
This table summarizes KRTAP22-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP22-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP22-2 shows higher tumor expression in PRAD. The PRAD box plot shows higher KRTAP22-2 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .041).
This table shows molecular features associated with KRTAP22-2 in patient tissues and cancer cell lines. In patient samples, KRTAP22-2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP22-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and STOMACH.
